PGC-1β modulates statin-associated myotoxicity in mice by Singh, François et al.
Vol.:(0123456789) 
Archives of Toxicology (2019) 93:487–504 
https://doi.org/10.1007/s00204-018-2369-7
ORGAN TOXICITY AND MECHANISMS
PGC-1β modulates statin-associated myotoxicity in mice
François Singh1,2 · Joffrey Zoll2 · Urs Duthaler1 · Anne‑Laure Charles2 · Miljenko V. Panajatovic1,2 · Gilles Laverny4 · 
Thomas G. McWilliams5 · Daniel Metzger4 · Bernard Geny2 · Stephan Krähenbühl1,3  · Jamal Bouitbir1,3 
Received: 27 July 2018 / Accepted: 29 November 2018 / Published online: 3 December 2018 
© Springer-Verlag GmbH Germany, part of Springer Nature 2018
Abstract
Statins inhibit cholesterol biosynthesis and lower serum LDL-cholesterol levels. Statins are generally well tolerated, but 
can be associated with potentially life-threatening myopathy of unknown mechanism. We have shown previously that 
statins impair PGC-1β expression in human and rat skeletal muscle, suggesting that PGC-1β may play a role in statin-
induced myopathy. PGC-1β is a transcriptional co-regulator controlling the expression of important genes in mitochondrial 
biogenesis, antioxidative capacity and energy metabolism. The principle aim of the current study was to investigate the 
interaction between atorvastatin and PGC-1β in more detail. We therefore treated wild-type mice and mice with selective 
skeletal muscle knockout of PGC-1β (PGC-1β(i)skm−/− mice) with oral atorvastatin (5 mg/kg/day) for 2 weeks. At the end of 
treatment, we determined body parameters, muscle function, structure, and composition as well as the function of muscle 
mitochondria, mitochondrial biogenesis and activation of apoptotic pathways. In wild-type mice, atorvastatin selectively 
impaired mitochondrial function in glycolytic muscle and caused a conversion of oxidative type IIA to glycolytic type IIB 
myofibers. Conversely, in oxidative muscle of wild-type mice, atorvastatin enhanced mitochondrial function via activation of 
mitochondrial biogenesis pathways and decreased apoptosis. In PGC-1β(i)skm−/− mice, atorvastatin induced a switch towards 
glycolytic fibers, caused mitochondrial dysfunction, increased mitochondrial ROS production, impaired mitochondrial pro-
liferation and induced apoptosis in both glycolytic and oxidative skeletal muscle. Our work reveals that atorvastatin mainly 
affects glycolytic muscle in wild-type mice and demonstrates the importance of PGC-1β for oxidative muscle integrity during 
long-term exposure to a myotoxic agent.
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Abbreviations
CK  Creatine kinase
FRL  Free radical leak
HMG-CoA  3-Hydroxy-3-methylglutaryl-coenzyme A
MHC  Myosin heavy chain
mtDNA  Mitochondrial DNA
NADH  Nicotinamide adenine dinucleotide 
(reduced)
OXPHOS  Oxidative phosphorylation
PGC  Peroxisome proliferator-activated receptor-γ 
co-activator
ROS  Reactive oxygen species
Introduction
Statins inhibit HMG-CoA reductase, the rate-limiting 
enzyme of cholesterol synthesis, mainly in the liver (McK-
enney 2003). The reduction of the hepatocellular cholesterol 
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pool triggers LDL receptor synthesis and transport to the 
plasma membrane, leading to increased hepatocellular 
uptake, and therefore lowering, of serum LDL-cholesterol 
(Krähenbühl et al. 2016). Although the clinical benefits 
of statins in lowering LDL-cholesterol are well-described 
(Cholesterol Treatment Trialists’ (CTT) Collaboration et al. 
2010; Cholesterol Treatment Trialists’ (CTT) Collaborators 
et al. 2012), muscle toxicity affects up to one in four patients 
undergoing treatment (termed statin-associated muscle 
symptoms or myopathy) (Alfirevic et al. 2014; Thompson 
et al. 2016). The clinical severity of statin-associated myo-
pathy ranges from an asymptomatic elevation of creatine 
kinase (CK) activity to fatal rhabdomyolysis (Alfirevic et al. 
2014).
Several studies have shown that mitochondrial dysfunc-
tion is an important component of statin-associated skel-
etal muscle damage (Larsen et al. 2013; Singh et al. 2015; 
Bouitbir et al. 2016). Mitochondrial dysfunction, in par-
ticular impaired function of the electron transport chain, is 
frequently associated with increased production of reactive 
oxygen species (ROS). Importantly, increased mitochondrial 
production of ROS can further damage the constituents of 
the electron transport chain and can trigger cell death by 
apoptosis or necrosis. Short-term exposure of L6 myoblasts 
and long-term treatment of rats and humans with statins has 
been shown to be associated with increased ROS produc-
tion in skeletal muscle (Bouitbir et al. 2016). Mitochondrial 
content appears to play a key role in susceptibility to statin-
induced myopathy (Singh et al. 2015; Bouitbir et al. 2016). 
Mitochondria-rich oxidative muscle exhibits resistance to 
statin-induced myopathy, whereas glycolytic muscle is sus-
ceptible to damage (Bouitbir et al. 2016). Inhibition of mito-
chondrial biogenesis by statins has been demonstrated, since 
skeletal muscle mitochondrial DNA is decreased in patients 
with statin-induced myopathy (Schick et al. 2007; Stringer 
et al. 2013). The maintenance of mitochondrial content and 
biogenesis in mammals depends upon the coordinated activ-
ity of transcriptional regulators such as peroxisome prolifer-
ator-activated receptor γ co-activator 1 (PGC-1) α and β (Lin 
et al. 2002a; Puigserver and Spiegelman 2003; Ljubicic et al. 
2010). While PGC-1α has been studied extensively in skel-
etal muscle, the precise role of PGC-1β here has not been 
completely clarified (Zechner et al. 2010; Handschin and 
Spiegelman 2011; Rowe et al. 2013). Recently, we showed 
that PGC-1β orchestrates the muscle-specific transcription 
of several genes known to influence mitochondrial metabo-
lism and oxidative stress responses (Gali Ramamoorthy et al. 
2015).
Given these new insights and taking into account that 
atorvastatin inhibited PGC-1β expression (Bouitbir et al. 
2016), we hypothesized that PGC-1β may play a role in 
modulating statin-associated myotoxicity. In the present 
study, we addressed this question by employing the recently 
described PGC-1β(i)skm−/− model, which enables the tissue-
specific ablation of PGC-1β from skeletal muscle in mice 
(Gali Ramamoorthy et al. 2015). For that, we treated wild-
type and PGC-1β(i)skm−/− mice with atorvastatin for 14 days 
and investigated the function, composition and morphology 
of white and red skeletal muscles. In both wild-type and 
mutant mice, statin treatment markedly impaired skeletal 
muscle function. Our data demonstrated that PGC-1β plays 
an important role in modulating mitochondrial homeostasis 
following long-term treatment with atorvastatin, particularly 
in oxidative skeletal muscle. Additionally, we found that 
antioxidative capacity, mitochondrial content and the abil-
ity to trigger mitochondrial adaptive pathways are important 
factors for the protection from statin-associated myotoxicity. 
Our results provide valuable new insights into homeostatic 




Experiments were performed on adult mice (18–23 weeks 
at the beginning of the study; ~ 30 to 35 g). Generation 
of PGC-1β(i)skm−/− mice, in which PGC-1β is selectively 
ablated in skeletal muscle myofibers at adulthood, has 
been described previously (Gali Ramamoorthy et al. 2015). 
Briefly, chimeric males were bred with flippase (FLP)-
expressing females, to generate heterozygous PGC-1βL2/+ 
mice [bearing one PGC-1βL2 allele and one wild-type (WT; 
+) allele]. PGC-1βL2/+ mice were bred with C57BL/6 HAS-
Cre-ERT2(tf/0) transgenic mice that express the tamoxifen-
dependent Cre-ERT2 recombinase under the control of HAS 
regulatory elements. Their offsprings were intercrossed to 
generate HSA-Cre-ERT2(tg/0)/PGC-1βL2/L2 pre-mutant mice 
and HSA-Cre-ERT2(0/0)/PGC-1βL2/L2 control mice. Pre-
mutant male mice and sex-matched control littermates were 
intraperitoneally injected with tamoxifen (1 mg/day, for 
5 days) at 7 weeks of age.
Animals were housed in a neutral temperature environ-
ment (22° ± 2 °C) on a 12:12 h photoperiod and had free 
access to food and water. Breeding and maintenance of 
mice were performed in the accredited IGBMC/ICS animal 
house (C67-2018-37 notification of 16/10/2013), in com-
pliance with French and EU regulations on the use of labo-
ratory animals for research, under the supervision of D. M. 
who holds animal experimentation authorizations from the 
French Ministry of agriculture and Fisheries (N°67–209 
and A 67–227). All animal experiments were approved by 
the Ethics Committee Com’Eth (Comité d’Ethique pour 
l’Expérimentation Animale, Strasbourg, France). Atorv-
astatin  (Tahor®) was generously provided by Pfizer. 43 
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mice were randomly divided in 4 groups as follows: (1) 
wild-type control mice (untreated wild-type mice; n = 13); 
(2) wild-type mice treated with atorvastatin 5 mg/kg/day in 
drinking water for 2 weeks (atorvastatin-treated wild-type 
mice, n = 11); (3) PGC-1β(i)skm−/− mice (untreated PGC-
1β(i)skm−/− mice, n = 8); (4) PGC-1β(i)skm−/− treated with 
atorvastatin 5 mg/kg/day in drinking water for 2 weeks 
(atorvastatin-treated PGC-1β(i)skm−/− mice, n = 11). Water 
intake was monitored twice a week by weighing the water 
bottle. No difference in water intake was found between 
groups. The atorvastatin concentration in the drinking 
water was between 30 and 40 mg/L (adjusted to the water 
consumption of the mice). The 5 mg/kg/day dose of atorv-
astatin was calculated as described by Reagan-Shaw et al. 
(Reagan-Shaw et al. 2008) and corresponds in humans 
to 0.405 mg/kg/day which is a commonly used dose in 
patients providing a reduction in low-density lipoprotein 
cholesterol above 40% (Law et al. 2003).
Sample collection
Animals were killed by cervical dislocation and tissues 
were immediately collected, weighed, and a part of each 
muscle tissue was immediately frozen in isopentane cooled 
by liquid nitrogen and stored at − 80 °C for later analysis, 
or processed for biochemical and histological analysis. 
The oxidative soleus muscle and the glycolytic superfi-
cial part of the gastrocnemius muscle were excised and 
cleaned of adipose and connective tissues. We conducted 
our experiments on different muscles, separating them 
by muscle type. Muscles are classified by mitochondrial 
mass. We used the superficial part of the gastrocnemius 
muscle, which is mostly glycolytic, with a low mitochon-
drial content. For the oxidative-type muscles with a high 
mitochondrial content, we studied the soleus muscle, and 
the vastus intermedius (the most oxidative part of the 
quadriceps, which is located close to the femur bone).
Plasma biochemistry
Blood was collected by cardiac puncture immediately after 
death in ethylenediaminetetracetic acid (EDTA)-rinsed 
tubes and then centrifuged at 1100 g for 15 min at 4 °C. 
The plasma was separated and stored at − 80 °C until anal-
ysis. The analysis of plasma biochemical parameters was 
performed on randomly selected plasma samples. Plas-
matic creatine kinase activity was determined using the 
Creatine Kinase Activity Assay Kit from Sigma-Aldrich 
(MAK116; St Louis, USA), according to the manufac-
turer’s instructions.
Atorvastatin plasma and skeletal muscle 
concentrations
Atorvastatin was analyzed on an UHPLC system (Shimadzu, 
Kyoto, Japan) connected to an API 5500 tandem mass spec-
trometer (AB Sciex, Ontario, Canada). The UHPLC system 
consisted of four LC-30AD pumps, a SIL-30AC autosam-
pler, a CTO-20AC column oven, a DGU-20A5 degassing 
unit, and a CBM-20A controller. Chromatography was per-
formed on a kinetex 2.6 µm F5 100 Å (50 × 2.1 mm) analyti-
cal column (Phenomenex, Torrance, USA). Mobile phase A 
consisted of water plus 0.1% formic acid, while mobile phase 
B was methanol-supplemented with 0.1% formic acid. The 
following gradient program of mobile phase B was applied: 
40% (0–0.25 min), 95% (0.25–1.5 min), 95% (1.5–2.0 min), 
40% (2.0–2.25 min). The flow rate was set at 0.4 mL/min at 
40 °C. The introduced sample was pre-column diluted with 
water 0.1% formic acid during the first 0.25 min of each 
run. Atorvastatin eluted after 1.7 min, hence the UHPLC 
was only connected from minute 1–2 with the mass spec-
trometer to avoid superfluous contamination of the system. 
Atorvastatin and atorvastatin-d5 were detected by multiple 
reaction monitoring using electrospray ionization in the 
positive mode. A mass transition of 559.1 → 440.1 m/z and 
564.1 → 445.1 was used for atorvastatin and atorvastatin-d5, 
respectively (dwell time: 25 msec, declustering potential: 
126 V, entrance potential: 10 V, collision energy: 33 V, cell 
exit potential: 30 V). The mass spectrometer was operated 
at an ion source gas 1 of 45 L/min (N2), an ion source gas 2 
of 60 L/min (N2), a curtain gas of 30 L/min, a collision gas 
set to medium (N2), an ion spray voltage of 4500 V, and a 
source temperature of 350 °C. Analyst software 1.6.2 (AB 
Sciex, Ontario, Canada) was used to control the LC-MS/
MS system. Calibration lines were prepared in blank mouse 
plasma or blank muscle extracts. Thereby, blank plasma 
or muscle extracts were spiked with atorvastatin at a final 
concentration of 2242 nM and serially diluted to 4.4 nM 
(≤ 1% DMSO). For muscle extracts, 5–10 mg gastrocnemius 
muscle (glycolytic) was homogenized in 1 mL water. After 
centrifugation (4000 rpm during 30 min, Eppendorf 5810R, 
Hamburg, Germany), 700 µL supernatant was evaporated at 
50 °C. After addition of 150 µL methanol 0.1% formic acid 
containing the internal standard (atorvastatin-d5: 25 nM) 
and mixing with a VX-2500 multi-tube vortexer (VWR, 
Dietikon, Switzerland) for 1 min, samples were centrifuged 
(4000 rpm during 30 min, Eppendorf 5810R, Hamburg, 
Germany). Plasma aliquots of 10 µL were precipitated with 
150 µL methanol 0.1% formic acid containing the internal 
standard (atorvastatin-d5: 25 nM). Samples were mixed with 
a VX-2500 multi-tube vortexer (VWR, Dietikon, Switzer-
land) for about 1 min and centrifuged at 4000 rpm during 
30 min (Eppendorf 5810R, Hamburg, Germany). 10 µL 
supernatant was injected into the LC–MS/MS system. The 
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lower limit of detection was 5 pmol/L, the linearity of the 
method from 5 pmol/L to 10 nmol/L and variability was 
less than 15%.
Grip strength test
A Grip Strength Meter (Bioseb, Vitrolles, France) was used 
to measure combined forelimb and hindlimb grip strength. 
The test was repeated three consecutive times within the 
same session, and the mean value was recorded as the maxi-
mal grip strength for each mouse. All tests were performed 
by the same operator.
Histology
The analysis of all histological parameters was performed 
on randomly selected slide samples. Hematoxylin and eosin 
staining was performed on 10 µm frozen sections of 3–4 
samples per group on the glycolytic muscle gastrocnemius, 
and the more oxidative-type vastus intermedius muscle. 
Hematoxylin and eosin staining photographs were captured 
on an Olympus IX83 microscope (Olympus, Hamburg, Ger-
many). Evaluation and interpretation of the results were real-
ized according to the MDC1A_M.1.2.004 SOP. Fiber area 
was measured on pictures obtained with a 20 × objective, 
using the cellSens Dimension software (Olympus, Hamburg, 
Germany), by carefully manually tracing the circumference 
of each individual fiber. The number of fibers measured 
for each individual sample ranged from 45 to 110 fibers 
(mean = 63). Illustrations provided in the figures have been 
obtained with a 40 × objective. Presence of central nuclei 
was confirmed by color deconvolution using the ImageJ 
software (National Institute of Health) to exclude staining 
artefacts.
NADH diaphorase staining was performed on 10 µm fro-
zen sections of 3–4 samples per group, on the glycolytic 
muscle gastrocnemius, and the more oxidative-type vastus 
intermedius muscle. NADH staining photographs were cap-
tured on an Olympus IX83 microscope (Olympus, Hamburg, 
Germany). Determination of the percentage of stained fibers 
was carefully performed by manual counting on pictures 
obtained with a 10 × objective. The number of fibers counted 
for each individual sample ranged from 1144 to 1785 fib-
ers (mean = 1507). Illustrations provided in the figures have 
been obtained with a 20 × objective.
Myosin heavy chain expression 
immunofluorescence
Immunofluorescence analysis of MHC expression was 
performed as described by (Bloemberg and Quadrilat-
ero 2012), on 10 µm frozen sections of three samples per 
group on the glycolytic muscle gastrocnemius, and the 
more oxidative-type vastus intermedius muscle. Primary 
antibodies against MHCI (BA-F8, 1/50), MHCIIA (SC-71, 
1/600), and MHCIIB (BF-F3, 1/100) were purchased from 
the Developmental Studies Hybridoma Bank (University of 
Iowa), whereas secondary antibodies were purchased from 
ThermoFisher scientific (A21140: goat anti-mouse IgG2b 
secondary antibody, Alexa  Fluor® 350 conjugate; A21121: 
goat anti-mouse IgG1 secondary antibody, Alexa  Fluor® 488 
conjugate; and A21426: goat anti-mouse IgM heavy chain 
secondary antibody, Alexa  Fluor® 555 conjugate). All anti-
body cocktails were prepared in block solution (10% goat 
serum (Gibco) in PBS). Briefly, slides were incubated with 
block solution for 1 h. Primary antibody cocktail was then 
applied, and slides were incubated for 2 h. After PBS wash, 
secondary antibody cocktail was applied, and slides were 
incubated for 1 h. After PBS wash, slides were mounted 
with coverslips, using  Prolong® Gold antifade reagent (Ther-
moFisher scientific, Waltham, MA, USA). MHC immuno-
fluorescence pictures were captured on an Olympus IX83 
microscope (Olympus, Hamburg, Germany). Determina-
tion of the percentage of type I, IIA, IIAX, IIX, IIXB, and 
IIB fibers was performed by manual counting on pictures 
obtained with a 20 × objective. For each individual sample, 
between 197 and 594 fibers (mean = 361) in the gastroc-
nemius, and between 110 and 737 fibers (mean = 236) in 
the vastus intermedius were carefully manually counted to 
determine the proportion of each fiber type in the respective 
muscle. Merged illustrations provided in the figures have 
been obtained with a 40 × objective.
Study of muscle mitochondrial respiration
This technique ensured determination of global mitochon-
drial function, reflecting both the density as well as the 
functional properties of the muscle mitochondria (Vek-
sler et al. 1987). The mitochondrial respiration was stud-
ied from saponin-skinned fibers that keep mitochondria 
in their architectural environment, in superficial gastroc-
nemius, and soleus muscles. The analysis took place in a 
thermostated oxygraphic chamber at 37 °C with continuous 
stirring (Oxygraph-2k, Oroboros instruments, Innsbruck, 
Austria). Approximately 2 mg of fibers was placed in respi-
ration medium [2.77 mM  CaK2EGTA, 7.23 mM  K2EGTA, 
6.56 mM  MgCl2, 20 mM imidazole, 20 mM taurine, 0.5 mM 
dithiothreitol, 50 mM K-methane sulfonate, 5 mM gluta-
mate, 2 mM malate, 3 mM phosphate, and 2 mg/mL of 
bovine serum albumin (BSA); pH 7] in the oxygraphic 
chamber. After the determination of the basal oxygen 
consumption with glutamate (5 mM) and malate (2 mM) 
(Basal), OXPHOS  CI-linked substrate-state was measured in 
the presence of saturating amount of adenosine diphosphate 
(2 mM ADP). When OXPHOS  CI-linked substrate-state was 
recorded, electron flow went through complexes I, III, and 
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IV The maximal OXPHOS respiration rate  CI+II-linked sub-
strate state was then measured by adding succinate (25 mM). 
Complex I was blocked with rotenone (0.5 µM), allowing 
to measure OXPHOS  CII-linked substrate state. Respiratory 
rates were expressed as pmol  O2 × s−1 × mg−1 wet weight. 
Respiratory acceptor control ratio (RCR) was determined 
by calculating state 3/state 4 respiratory rates.
Mitochondrial  H2O2 production in permeabilized 
fibers
H2O2 production was studied from saponin-skinned fibers 
that keep mitochondria in their architectural environment, 
in superficial gastrocnemius, and soleus muscles. The per-
meabilized bundles were placed in ice-cold buffer Z con-
taining 110 mM K-methane sulfonate, 35 mM KCl, 1 mM 
EGTA, 5 mM  K2HPO4, 3 mM  MgCl2, 6 mM  H2O, 0.05 mM 
glutamate, and 0.02 mM malate with 0.5 mg/mL BSA (pH 
7.1, 295 mOsmol/kg  H2O).  H2O2 production was measured 
with Amplex Red (Invitrogen Life Technologies, Rockville, 
MD, USA), which reacted with  H2O2 in a 1:1 stoichiometry 
catalyzed by HRP (horseradish peroxidase; Invitrogen Life 
Technologies, Rockville, MD, USA) to yield the fluorescent 
compound resorufin and a molar equivalent of  O2 (Anderson 
and Neufer 2006). Resorufin has excitation and emission 
wavelengths of 563 nm and 587 nm, respectively, and is 
extremely stable once formed. Fluorescence was measured 
continuously with a Fluoromax 3 (Jobin Yvon) spectrofluor-
ometer with temperature control and magnetic stirring. After 
a baseline (reactants only) was established, the reaction was 
initiated by adding a permeabilized fiber bundle to 600 µL 
of buffer Z. Buffer Z contained 5 mM Amplex Red, 0.5 U/
mL HRP, 5 mM glutamate, and 2 mM malate as substrates at 
37 °C. Succinate (25 mM) was then added for the measure-
ment of  H2O2 production under reverse electron flux con-
dition. ADP (2 mM) was added to determine  CI+II-linked 
substrate-state  H2O2 production for the determination of the 
free radical leak (FRL) At the conclusion of each experi-
ment. The results were reported in pmol  H2O2 × s−1 × mg−1 
wet weight.
Free radical leak
H2O2 production and  O2 consumption were measured in 
parallel under similar experimental conditions  (CI+II-linked 
substrate state). This allowed the calculation of the fraction 
of electrons out of sequence which reduce  O2 to ROS in 
the respiratory chain (the percentage of free radical leak) 
instead of reaching cytochrome oxidase to reduce  O2 to 
water (Anderson and Neufer 2006). Because two electrons 
are needed to reduce one mole of  O2 to  H2O2, whereas four 
electrons are transferred in the reduction of one mole of  O2 
to water, the percent of FRL was calculated as the rate of 
 H2O2 production divided by twice the rate of  O2 consump-
tion, and the result was multiplied by 100.
Quantitative real‑time polymerase chain reaction 
(qRT‑PCR)
Total RNA was obtained from superficial gastrocnemius and 
the oxidative part of the quadriceps muscles of six random 
samples per group, using the RNeasy Fibrous Tissue Mini 
Kit (QIAGEN Gmbh, Hilden, Germany) according to the 
manufacturer’s instructions. RNA was stored at − 80 °C until 
the reverse transcription reaction was performed. cDNA 
was synthetized from 1 µg total RNA with the Omniscript 
RT kit (QIAGEN Gmbh, Hilden, Germany). To perform 
the real-time PCR reaction, cDNA was mixed with each 
primer [sense and antisense (0.3 µM final concentration), 
SYBR Green (Roche Diagnostics, Mannheim, Germany)] 
as a fluorescent dye and  H2O. The real-time PCR measure-
ment of individual cDNAs was performed in triplicate using 
SYBR Green dye to measure duplex DNA formation with 
the ViiA™ 7 Real-Time PCR System (Applied Biosystems, 
Waltham, MA, USA). The primers sequences were designed 
using information contained in the public database Gen-
Bank of the National Center for Biotechnology Information 
(NCBI). The sequences of the primer sets used are listed in 
Table 1. Quantification of gene expression was performed 
by the method described in Liu and Saint (2002), using the 
18S gene as the internal control. The amplification efficiency 
Table 1  Primer list for quantitative real-time PCR amplification
Gene Organism Forward primer Reverse primer
COX2 Mouse GTT GAT AAC CGA GTC GTT CTG C CCT GGG ATG GCA TCA GTT TT
Hk2 Mouse GCC AGC CTC TCC TGA TTT TAG TGT GGG AAC ACA AAA GAC CTC TTC TGG 
PGC-1α Mouse AAT GCA GCG GTC TTA GCA CT ACG TCT TTG TGG CTT TTG CT
PGC-1β Mouse TGC GGA GAC ACA GAT GAA GA GGC TTG TAT GGA GGT GTG GT
NRF1 Mouse TTA CTC TGC TGT GGC TGA TGG CCT CTG ATG CTT GCG TCG TCT 
NRF2 Mouse CGA GAT ATA CGC AGG AGA GGT AAG A GCT CGA CAA TGT TCT CCA GCT T
TFAm Mouse GCT GAT GGG TAT GGA GAA G GAG CCG AAT CAT CCT TTG C
18 s Mouse TCG TCT TCG AAA CTC CGA CT CGC GGT TCT ATT TTG TTG GT
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of each sample was calculated as described by Ramakers 
et al. (2003).
GSH content
GSH content was determined in superficial gastrocnemius 
and the oxidative part of quadriceps muscles (10 mg) using 
the GSH-Glo Glutathione Assay kit from Promega, follow-
ing the manufacturer’s instructions.
Western blotting
Approximately 20 mg of mouse skeletal muscle (superfi-
cial gastrocnemius and the oxidative part of the quadriceps) 
was homogenized with a microdismembrator for 1 min at 
2000 rpm (Sartorius Stedim Biotech, Aubagne, France). 
Muscle homogenates were then lysed on ice for 15 min 
with (100 µL/mg tissue) of RIPA buffer [50 mM Tris–HCl 
pH 7.4, 150 mM NaCl, 50 mM NaF, 2 mM EDTA, 1% 
NP-40, 0.5% Na-deoxycholate, 0.1% SDS, and Complete 
Mini protease inhibitor (Roche, Basel, Switzerland)]. After 
lysis, the mixture was vortexed and centrifuged for 10 min 
at 4 °C at 10,000 rpm. The supernatant was collected and 
the protein concentration determined using the Pierce BCA 
protein assay kit (ThermoFisher Scientific, Waltham, MA, 
USA). For each sample, 9 µg of protein was separated on 
a NuPAGE 4–12% Bis-Tris gel (Life technologies, Rock-
ville, MD, USA). Proteins were electroblotted to PVDF 
membranes (Bio-Rad), and immunodetected using primary 
antibodies directed against PGC-1α (KP9803, calbiochem, 
1/1000), PGC-1β (sc-373771, santa cruz, 1/1000), TFAm 
(ab131607, abcam, 1/1000), TOMM20 (ab78547, abcam, 
1/1000), Cytochrome b (sc-11436, santa cruz, 1/1000), 
SOD2 (#13194, cell signaling, 1/2000), full and cleaved Cas-
pase 3 (#9665S, cell signaling, 1/500), and Beta Actin (sc-
130656, santa cruz, 1/1000). Membranes were probed with 
secondary antibodies conjugated to HRP directed against 
goat (sc-2020, santa cruz, 1/2000), rabbit (sc-2004, santa 
cruz, 1/2000), and mouse (sc-2055, santa cruz, 1/2000). 
Membranes were revealed with a chemiluminescent sub-
strate (Clarity Western ECL substrate; Bio-Rad Laborato-
ries, Hercules, CA, USA), and quantification was performed 
using the ImageJ software (National Institute of Health). 
Images were modified with ImageJ to remove background.
mtDNA content
DNA was isolated from gastrocnemius and quadriceps mus-
cles of six random samples per group, using the DNeasy 
Blood and Tissue Kit (QIAGEN Gmbh, Hilden, Germany) 
according to the manufacturer’s instructions. DNA in sam-
ples was quantified spectrophotometrically at 260 nm with a 
NanoDrop 2000 (ThermoFisher scientific, Waltham, USA). 
The DNA was subjected to real-time PCR in triplicate 
(10 ng/µL). Relative amounts of nuclear and mitochondrial 
DNA were determined by comparison of amplification kinet-
ics of Hexokinase 2 (Hk2) and COX2 [primer sequences in 
Table S1, as described by (Gariani et al. 2015)]. mtDNA 
content was estimated by calculating the inverse of the 
 CTCOX2/CTHk2 ratio.
TUNEL assessment of apoptosis
TUNEL staining of myonuclei positive for DNA strand 
breaks was performed using the Click-iT® TUNEL Alexa 
 Fluor® 647 Imaging Assay kit (ThermoFisher Scientific, 
Waltham, MA, USA) on randomly selected slides sam-
ples. Cross-sections (10 µm) of three samples per group 
of the glycolytic muscle gastrocnemius, and the more oxi-
dative-type vastus intermedius muscle cut with a cryostat 
microtome were fixed with 4% paraformaldehyde for 15 min 
and permeabilized with 2 mg/mL proteinase K. The TUNEL 
reaction mixture containing terminal deoxynucleotidyltrans-
ferase (TdT) and fluorescein-labeled dUTP was added to the 
sections in portions of 100 µL and then incubated for 60 min 
at 37 °C in a humidified chamber in the dark. Sections were 
then washed with 3% BSA and 0.1% Triton X-100 in PBS 
for 5 min, and incubated for 30 min at 37 °C protected from 
light with the Click-iT® Plus TUNEL reaction cocktail. After 
incubation, the sections were rinsed with PBS. Following 
embedding with ProLong diamond antifade mountant with 
DAPI (Life Technologies), the sections were investigated 
with a fluorescence microscope (× 40 objective; Olympus 
IX83). Three-to-five pictures were acquired per sample. 
After acquisition, background noise was removed using the 
ImageJ software (National Institutes of Health). The num-
ber of TUNEL-stained nuclei was manually determined to 
avoid artefact detection, whereas the total number of nuclei 
count was automated using the Icy software (v1.9.4.1) (de 
Chaumont et al. 2012). Apoptotic index was calculated by 
counting the number of TUNEL-stained nuclei divided by 
the total number of nuclei multiplied by 100.
Statistics
Data are represented as mean values ± SEM. Statistical 
analyses were performed using unpaired t test or two-way 
ANOVA followed by a Bonferroni’s post-test between 
atorvastatin-treated mice in comparison to their respective 
controls using GraphPad Prism 5 (Graph Pad Software, Inc., 
San Diego, CA, USA). Statistics were then verified using 
RStudio (RStudio Team (2016). Two-way ANOVA inter-
action effects are displayed on figures with dashed lines. 
Statistical significance is displayed as *p < 0.05: **p < 0.01 
and ***p < 0.001.
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Results
Atorvastatin treatment induced muscle damage 
and metabolic switching
To investigate the exposure to atorvastatin, we analyzed 
plasma and gastrocnemius muscle atorvastatin concentra-
tions by LC–MS/MS. Suppl. Table 1 shows the atorvasta-
tin concentration in gastrocnemius and the corresponding 
plasma concentration for the mice for which tissue and/or 
plasma was available. In mice not treated with atorvastatin, 
we did not detect any atorvastatin in plasma or skeletal 
muscle. For wild type and PGC-1β(i)skm−/− mice treated 
with atorvastatin we pooled the plasma and skeletal muscle 
concentration data, since they were not different between 
the two groups (Suppl. Table 1). The plasma concentration 
was 15.7 (9.1–32.6) nM (median and range) and the skele-
tal muscle concentration 3.2 (1.1–234) nmol/kg. Assuming 
a half-life for atorvastatin in mice of 30 min (Higgins et al. 
2014; Chang et al. 2014), the best explanation for the high 
variability in the skeletal muscle atorvastatin concentration 
is the gap between removal of the water supply (which con-
tained atorvastatin) and euthanasia, which was 3 h on the 
average. The plasma concentrations are comparable to what 
is observed in patients (Björkhem-Bergman et al. 2011) and 
the skeletal muscle concentrations are slightly below the 
 IC50 for the inhibition of HMG-CoA reductase, which is in 
the range of 8 nM (McKenney 2003).
Plasma creatine kinase activity reflects muscle damage and 
can be used as a biomarker for the detection of drug-induced 
myopathy. Atorvastatin treatment increased the plasma 
creatine kinase activity in both wild type and PGC-1β(i)
skm−/− mice, reaching statistical significance for atorvastatin-
treated compared to untreated PGC-1β(i)skm−/− mice (Fig. 1a). 
This finding suggested the existence of atorvastatin-associated 
muscle alterations, particularly in PGC-1β(i)skm−/− mice. To 
confirm this by functional means, we performed grip strength 
tests, and observed that treatment with atorvastatin decreased 
the force in both groups compared to their respective untreated 
control group (Fig. 1b). No differences were found in the body 
weight at the end of the protocol between the groups (Fig. 1c), 
suggesting that the observed decrease in muscle strength was 
specific to muscle dysfunction, and not merely a general effect 
on the animals.
To investigate the cause for muscle dysfunction, we per-
formed hematoxylin and eosin staining on sections of two 
metabolically distinct hindlimb muscles: the superficial gas-
trocnemius (mostly glycolytic) and the vastus intermedius 
(mostly oxidative). The fiber area was decreased in the glyc-
olytic muscle (gastrocnemius) (Fig. 2a) of both atorvastatin-
treated wild type and PGC-1β(i)skm−/− mice compared to their 
respective untreated control group. Interestingly, atorvastatin 
also decreased also the fiber area of oxidative muscle (vastus 
intermedius) in PGC-1β(i)skm−/− mice, but not in wild-type 
mice (Fig. 2b).
To understand better the relationship between fiber type 
and statin toxicity, we determined the myosin heavy chain 
Fig. 1  Atorvastatin treatment 
impaired skeletal muscle 
function. a Plasma creatine 
kinase activity. b Forelimb and 
hindlimb peak force. c Mice 
body weight at the end of the 
study. Results are expressed 
as mean ± SEM, *p < 0.05, 
**p < 0.01. WT-CTL: untreated 
wild-type mice (n = 13); WT-
ATO: wild-type mice treated 
with oral atorvastatin (5 mg/kg/
day) 2 weeks (n = 11); KO-CTL: 
untreated PGC-1β(i)skm−/− mice 
(n = 8); KO-ATO: PGC-1β(i)
skm−/− treated with oral atorvas-
tatin (5 mg/kg/day) for 2 weeks 
(n = 11)
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isoform (MHC) I, IIA, IIX, and IIB expression in both 
muscle types. In the glycolytic gastrocnemius muscle, both 
groups treated with atorvastatin exhibited a switch from IIA 
myofibers, which are characterized by mitochondrial abun-
dance and oxidative metabolism (Handschin et al. 2007), and 
IIAX myofibers towards IIB glycolytic myofibers (Fig. 3a). 
By comparison, in the oxidative vastus intermedius muscle, 
statins did not affect fiber-type composition in wild-type 
mice (Fig. 3b). However, in PGC-1β(i)skm−/− mice, atorv-
astatin induced a massive switch from fast-twitch oxidative 
IIA, IIAX, and IIX fibers towards IIB glycolytic myofibers.
Taken together, these data suggested that treatment with 
atorvastatin caused a switch from an oxidative to a glyco-
lytic fiber composition phenotype. This switch in fiber-type 
composition could theoretically increase the susceptibility to 
atorvastatin, since statins are known to impair mitochondrial 
function preferentially in glycolytic skeletal muscle (Bouit-
bir et al. 2012, 2016). We next sought to investigate mito-
chondrial function and mitochondrial adaptations in skeletal 
muscle of wild type and PGC-1β(i)skm−/− mice.
PGC‑1β modulated responses to atorvastatin 
in oxidative but not in glycolytic muscle
In agreement with previous results obtained in the glycolytic 
tibialis anterior muscle (Gali Ramamoorthy et al. 2015), his-
tochemical staining revealed decreased activity of mitochon-
drial complex I (NADH dehydrogenase) in the superficial 
gastrocnemius of PGC-1β(i)skm−/− mice (Fig. 4a). Moreover, 
treatment with atorvastatin was associated with decreased 
NADH dehydrogenase staining in the gastrocnemius mus-
cles of wild type and PGC-1β(i)skm−/− mice compared to their 
respective untreated control group, leading to an additive 
effect in atorvastatin-treated PGC-1β(i)skm−/− mice. The per-
centage of stained fibers was also decreased in the oxidative 
vastus intermedius muscle of atorvastatin-treated compared 
to the untreated PGC-1β(i)skm−/− mice (Fig. 4b). In contrast, 
there was no difference in NADH dehydrogenase stain-
ing of the vastus intermedius between atorvastatin-treated 
and untreated wild-type mice and between untreated PGC-
1β(i)skm−/− and wild-type mice.
Fig. 2  Impaired muscle structure and phenotype. Hematoxylin and 
eosin stainings and fiber area quantifications of a superficial gas-
trocnemius muscle sections (glycolytic), and b vastus intermedius 
(oxidative) muscle sections. White arrows indicate myofibers with 
central nuclei. Results are expressed as mean ± SEM; **p < 0.01, 
***p < 0.001. WT-CTL: untreated wild-type mice (n = 13); WT-ATO: 
wild-type mice treated with oral atorvastatin (5 mg/kg/day) 2 weeks 
(n = 11); KO-CTL: untreated PGC-1β(i)skm−/− mice (n = 8); KO-ATO: 
PGC-1β(i)skm−/− treated with oral atorvastatin (5  mg/kg/day) for 
2 weeks (n = 11)
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Based on these results, we determined the mitochon-
drial respiration rates in permeabilized fibers from both 
muscle types. Atorvastatin treatment for 2 weeks impaired 
the glycolytic muscle mitochondrial function in both wild 
type and PGC-1β(i)skm−/− mice (Fig. 5a). Although no dif-
ferences were found in the basal respiratory rates, atorv-
astatin decreased OXPHOS  CI-linked substrate-state  O2 
consumption in both wild type and PGC-1β(i)skm−/− groups 
compared to their respective untreated control group. In 
addition, maximal OXPHOS respiratory rates  (CI+II-linked 
substrate state) and  CII-linked substrate state were decreased 
by atorvastatin in PGC-1β(i)skm−/−, but not in the respective 
wild-type mice. In comparison, no significant differences 
were found in the respiratory control ratio (RCR) of the 
gastrocnemius (Fig. 5b). In the oxidative soleus muscle, 
atorvastatin impaired mitochondrial function only in PGC-
1β(i)skm−/− mice (Fig. 5c). Basal mitochondrial respiration 
as well as  CI-linked substrate state,  CI+II-linked substrate 
state, and  CII-linked substrate state were decreased in soleus 
of atorvastatin-treated compared to untreated PGC-1β(i)
skm−/− mice. Again, no differences were found in the soleus 
RCR (Fig. 5d).
As elevated mitochondrial  H2O2 production can be del-
eterious to mitochondrial function, we next assayed this 
in our mice. Under reverse electron flux conditions, mito-
chondrial  H2O2 production was increased in glycolytic 
gastrocnemius muscle of atorvastatin-treated wild type 
and PGC-1β(i)skm−/− mice compared to their respective 
untreated control group (Fig. 5e). In the oxidative soleus, 
 H2O2 production was increased in atorvastatin-treated mice 
compared to untreated PGC-1β(i)skm−/− mice (Fig. 5f), but 
not in the respective wild-type mice. These measurements 
enabled us to calculate the free radical leak (FRL), which 
was increased in the atorvastatin-treated glycolytic muscle 
Fig. 3  Atorvastatin induced a fiber type switch. a Fiber typing of 
superficial gastrocnemius fiber sections and quantification. b Fiber 
typing of vastus intermedius fiber sections and quantifications. a, b 
Shown are type I (blue), type IIA (green), type IIAX (intermediate 
green), type IIX (dark), type IIXB (intermediate red), and type IIB 
(red). Results are expressed as mean ± SEM; *p < 0.05, **p < 0.01, 
***p < 0.001. WT-CTL: untreated wild-type mice (n = 13); WT-ATO: 
wild-type mice treated with oral atorvastatin (5 mg/kg/day) 2 weeks 
(n = 11); KO-CTL: untreated PGC-1β(i)skm−/− mice (n = 8); KO-ATO: 
PGC-1β(i)skm−/− treated with oral atorvastatin (5  mg/kg/day) for 
2 weeks (n = 11). (Color figure online)
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of PGC-1β(i)skm−/− mice (Fig. 5g). The cellular reduced glu-
tathione (GSH) pool, an important constituent of the antioxi-
dative defense system, was decreased in the gastrocnemius 
of the PGC-1β(i)skm−/− vs. wild-type mice whereas we only 
observed a numerical decrease in both atorvastatin-treated 
compared to the respective untreated control groups. In the 
oxidative vastus intermedius, atorvastatin treatment affected 
the GSH pool differently in function of the mouse genotype, 
with a decrease only in PGC-1β(i)skm−/− mice (Fig. 5h).
Mitochondrial adaption is a key determinant 
of statin tolerance
To determine a consequence of oxidative stress, we inves-
tigated mitochondrial biogenesis in more detail. In the 
glycolytic gastrocnemius muscle, we observed an impair-
ment of mitochondrial biogenesis in atorvastatin-treated 
compared to untreated wild-type mice with a significant 
decrease of PGC-1α and PGC-1β mRNA levels, whereas 
the decrease in the mRNA levels of NRF1, TFAm, and 
NRF2 was not statistically significant (Fig. 6a). A similar 
impairment was detected in atorvastatin-treated mice com-
pared to untreated PGC-1β(i)skm−/− mice, with decreased 
PGC-1β (the PGC-1β mRNA expression in skeletal mus-
cle of PGC-1β(i)skm−/− mice originates mainly from stem 
cells), NRF2, and TFAm mRNA expression, whereas the 
numerical decrease in the mRNA expression of PGC-1α and 
NRF1 was not statistically significant. In contrast, in the 
oxidative vastus intermedius muscle (Fig. 6b), we observed 
an activation of mitochondrial biogenesis pathways, with 
elevated expression of PGC-1α, NRF1, NRF2, and TFAm 
in atorvastatin-treated mice compared to untreated wild-type 
mice. On the contrary, in PGC-1β(i)skm−/− mice, we observed 
a repression of the mitochondrial biogenesis pathway in the 
oxidative vastus intermedius muscle by atorvastatin, with 
reduced mRNA expression levels of PGC-1α, PGC-1β, and 
TFAm in atorvastatin-treated compared to untreated PGC-
1β(i)skm−/− mice.
The study of mitochondrial adaptations by western 
blotting confirmed our mRNA data. In the glycolytic 
Fig. 4  Atorvastatin impaired muscle phenotype in fiber type in the 
glycolytic skeletal muscle and in the oxidative skeletal muscle of 
PGC-1β-deficient mice. NADH diaphorase staining, and stained 
fibers percentage of a superficial gastrocnemius muscle sections, 
and b vastus intermedius muscle sections. Results are expressed as 
mean ± SEM; **p < 0.01, ***p < 0.001. WT-CTL: untreated wild-
type mice (n = 13); WT-ATO: wild-type mice treated with oral atorv-
astatin (5 mg/kg/day) 2 weeks (n = 11); KO-CTL: untreated PGC-1β(i)
skm−/− mice (n = 8); KO-ATO: PGC-1β(i)skm−/− treated with oral atorv-
astatin (5 mg/kg/day) for 2 weeks (n = 11)
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Fig. 5  Impaired mitochondrial respiratory chain and enhanced ROS 
production. Mitochondrial oxidative capacities (a, c), and mitochon-
drial respiratory acceptor control ratios (b, d) of (a, b) superficial 
gastrocnemius muscle, and (c, d) soleus muscle. Mitochondrial  H2O2 
production of e superficial gastrocnemius muscle, and f soleus mus-
cle. g Mitochondrial free radical leak. h Muscle content of reduced 
glutathione (GSH). Results are expressed as mean ± SEM; *p < 0.05. 
WT-CTL: untreated wild-type mice (n = 13); WT-ATO: wild-type 
mice treated with oral atorvastatin (5  mg/kg/day) 2  weeks (n = 11); 
KO-CTL: untreated PGC-1β(i)skm−/− mice (n = 8); KO-ATO: PGC-
1β(i)skm−/− treated with oral atorvastatin (5  mg/kg/day) for 2  weeks 
(n = 11)
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gastrocnemius muscle (Fig. 6c, e), we observed a decrease 
in mitochondrial biogenesis-linked proteins such as PGC-1α, 
PGC-1β, and TFAm in atorvastatin-treated compared to 
untreated wild-type mice. An impairment of mitochondrial 
biogenesis by atorvastatin was supported (Fig. 6c) and a 
significant decrease in the mtDNA content in atorvastatin-
treated mice by a decreased expression of SOD2 com-
pared to untreated wild-type mice (Fig. 6f). As previously 
described, SOD2 expression was decreased in the glyco-
lytic muscle of PGC-1β(i)skm−/− mice compared to wild-type 
mice (Gali Ramamoorthy et al. 2015). In the gastrocnemius 
muscle of atorvastatin-treated PGC-1β(i)skm−/− mice, we 
noticed a decrease in TOMM20 and a trend for a decrease 
in cytochrome b expression (Fig. 6c) as well as a decrease 
in the mtDNA content compared to untreated PGC-1β(i)
skm−/− mice (Fig. 6f). In the oxidative vastus intermedius 
muscle of wild-type mice treated with atorvastatin, we 
observed an increase in PGC-1β expression compared to 
untreated wild-type mice (Fig. 6f). In addition, we observed 
an increased expression of TOMM20 and cytochrome b and 
an increased mtDNA content (Fig. 6f), suggesting a stimula-
tion of mitochondrial biogenesis. In contrast, in oxidative 
muscle of PGC-1β(i)skm−/− mice, treatment with atorvasta-
tin caused a decrease in cytochrome b protein expression 
(Fig. 6d) and a decrease in the mtDNA content compared to 
untreated PGC-1β(i)skm−/− mice (Fig. 6f).
PGC‑1β protects oxidative muscle 
from statin‑induced apoptosis
Western blot analysis of caspase 3 (Fig. 7a) revealed an 
effect of atorvastatin treatment in the glycolytic gastrocne-
mius, with a twofold increase in the cleaved/total caspase 
3 ratio in atorvastatin-treated mice compared to untreated 
wild-type mice and a 2.2-fold increase in atorvastatin-treated 
mice compared to untreated PGC-1β(i)skm−/− mice. In the 
oxidative muscle, no differences were observed between 
atorvastatin-treated and untreated wild-type mice, but the 
ratio of cleaved/total caspase 3 was increased 2.2-fold in 
atorvastatin-treated mice compared to untreated PGC-
1β(i)skm−/− mice. To confirm the stimulation of apoptotic 
pathways by atorvastatin, we performed TUNEL staining 
(Fig. 7b–d), which revealed a similar effect in the glycolytic 
skeletal muscle, and in oxidative skeletal muscle. In wild-
type mice, TUNEL was consistent with previous reports in 
rats (Bouitbir et al. 2016), showing that atorvastatin induced 
DNA fragmentation in glycolytic (Fig. 7b, d) but not in oxi-
dative skeletal muscle (Fig. 7c, d). In contrast to these obser-
vations, in PGC-1β(i)skm−/− mice, treatment with atorvastatin 
caused a higher percentage of apoptotic nuclei in both gly-
colytic and oxidative-type skeletal muscle.
Discussion
Statins are among the most often prescribed medications 
globally. Although they are clearly beneficial in patients with 
cardiovascular diseases, they can lead to myopathy in a con-
siderable number of patients. With the exception of patients 
that do not tolerate statins, it is likely that statins will remain 
the most important drug class for lowering elevated LDL-
cholesterol serum concentrations also in the future (Krähen-
bühl et al. 2016). Since statin intolerance is most often a 
consequence of statin-associated myopathy, a better under-
standing of the molecular mechanisms of statin myotoxicity 
is important. Our work reveals new mechanisms how statins 
can affect the integrity of skeletal muscle according to its 
metabolic phenotype, and shows a role of PGC-1β in pro-
tecting oxidative muscle against statin myotoxicity.
The median skeletal muscle concentration in gastrocne-
mius of the mice treated with atorvastatin was 3.2 nmol/kg, 
a value below the  IC50 of HMG-CoA reductase, which is 
in the range of 8 nM (McKenney 2003). It has to be taken 
into account, however, that in mice, the half-life of atorvas-
tatin is in the range of 30 min (Higgins et al. 2014; Chang 
et al. 2014) and that the gap between the last possible intake 
of water (which contained the atorvastatin) and euthana-
sia was approximately 3 h. Back-calculation of the skeletal 
muscle concentrations during water intake (mice are mainly 
night-active) suggests skeletal muscle atorvastatin concen-
trations clearly exceed the  IC50 of HMG-CoA reductase by 
atorvastatin.
Treatment with atorvastatin decreased muscle strength 
and in parallel increased serum CK activity in wild type 
and in PGC-1β(i)skm−/− mice, indicating that atorvastatin 
can cause myotoxicity. Additionally, treatment with ator-
vastatin decreased the glycolytic muscle fiber area in both 
mouse models. These results are consistent with a num-
ber of previous studies (Hanai et al. 2007; Bonifacio et al. 
2015) showing statin-associated muscular atrophy in glyco-
lytic muscle. Hanai et al. described an increase in atrogin-1 
mRNA expression in patients with statin-induced muscle 
injury (Hanai et al. 2007), and a similar increase was also 
observed in C2C12 myotubes at the mRNA and protein 
Fig. 6  Effects of atorvastatin on mitochondrial biogenesis. a mRNA 
transcript levels in superficial gastrocnemius (b) and in vastus inter-
medius muscle. Values are relative to 18S expression. c Muscle 
protein expression levels in superficial gastrocnemius (d) and vas-
tus intermedius muscle. Values are relative to β-actin expression. 
e Immunoblots of PGC-1β, TFAm, TOMM20, cytochrome b and 
β-actin. f Mitochondrial DNA quantification. Results are expressed 
as mean ± SEM; *p < 0.05, **p < 0.01. WT-CTL: untreated wild-type 
mice (n = 13); WT-ATO: wild-type mice treated with oral atorvastatin 
(5 mg/kg/day) 2 weeks (n = 11); KO-CTL: untreated PGC-1β(i)skm−/− 
mice (n = 8); KO-ATO: PGC-1β(i)skm−/− treated with oral atorvastatin 
(5 mg/kg/day) for 2 weeks (n = 11). For the western blots (c, d) n = 3 
per group
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level (Bonifacio et al. 2015). In addition, Bonifacio et al. 
observed decreased phosphorylation of FoxO3, which regu-
lates atrogin-1 expression, and at same time the induction of 
an atrophic phenotype. Surprisingly, in PGC-1β(i)skm−/− mice 
we detected a decrease in the fiber area not only in the gly-
colytic, but also in oxidative muscle. The data of the cur-
rent study suggest that atorvastatin and loss of PGC-1β have 
additive effects on muscle wasting, explaining this finding in 
PGC-1β(i)skm−/− mice. In support of this notion, PGC-1β is 
known to suppress protein degradation (Brault et al. 2010) 
and decreased PGC-1β expression has been reported to be 
associated with muscle wasting (Correia et al. 2015). Future 
studies have to show whether suppression of protein degra-
dation by PGC-1β is linked to decreased FoxO3 transcrip-
tional activity.
The results of the current study also support the concept 
of a heterogeneous nature of mitochondria in muscle fiber 
types. We and others have shown that mitochondria in oxi-
dative muscle fibers adapt more readily to statin-associated 
toxicity than in glycolytic fibers (Westwood et al. 2005; 
Seachrist et al. 2005; Bouitbir et al. 2016). In our previous 
study, we have shown that the high resistance of oxidative 
muscle to atorvastatin-associated toxicity may be due to 
a more efficient antioxidative defense system in oxidative 
compared to glycolytic muscle (Bouitbir et al. 2016). Since 
loss of PGC-1β reduces the efficacy of the mitochondrial 
antioxidative defense system (Gali Ramamoorthy et  al. 
2015), it is comprehensible that oxidative muscles of PGC-
1β(i)skm−/− mice are more vulnerable to atorvastatin than 
oxidative muscles of wild-type mice.
Although overexpression of PGC-1β has been shown to 
promote the formation of type IIX fibers in skeletal muscle 
(Arany et al. 2007), PGC-1β deficiency did not affect fiber-
type composition (Gali Ramamoorthy et al. 2015). To date, 
the molecular regulation of fiber-type determination is only 
poorly understood. Factors proposed to drive the formation 
of oxidative myofibers include AMP-activated protein kinase 
(AMPK) and PGC-1α (Lin et al. 2002b; Röckl et al. 2007) 
but not PGC-1β (Gali Ramamoorthy et al. 2015). On the 
other hand, glycolytic muscle determination has been attrib-
uted to Akt activation using a mechanism involving Baf60c, 
a transcriptional cofactor enriched in fast-twitch muscle, and 
DEP domain-containing mTOR-interacting protein (Meng 
et al. 2013). However, the activation of Akt is impaired 
by statins in C2C12 myotubes mainly due to a reduced 
mTORC2 activity (Bonifacio et al. 2016). The observed shift 
from type IIA to type IIB fibers in atorvastatin-treated PGC-
1β(i)skm−/− mice must therefore involve different mechanisms 
than activation of Akt.
Maximal OXPHOS respiratory rate depends on con-
vergent electron flow through complexes I and II to the 
Q-junction of the electron transport chain (ETC) (Gnaiger 
2009). Statins can decrease the biosynthesis of ubiquinone 
by inhibiting the production of mevalonate, a precursor of 
ubiquinone. As demonstrated by the determination of the 
atorvastatin concentration, atorvastatin reached concentra-
tions above the  IC50 for HMG-CoA reductase in skeletal 
muscle (McKenney 2003), suggesting that the synthesis 
of cholesterol and intermediates such as ubiquinone was 
inhibited by atorvastatin. However, serum and skeletal 
muscle atorvastatin concentrations were not different 
between wild type and PGC-1β(i)skm−/− mice, suggesting 
similar effects on skeletal muscle ubiquinone biosynthe-
sis. Since we observed impaired function of the electron 
transport chain in PGC-1β(i)skm−/− mice in both oxida-
tive and glycolytic muscle, but only in glycolytic mus-
cle in wild-type mice, a decrease in the skeletal muscle 
ubiquinone content may not be the only explanation for 
the observed mitochondrial dysfunction. In support of 
this assumption, it appears that in most patients treated 
with statins, the skeletal muscle  CoQ10 content remains 
high enough to maintain the ETC function (Banach et al. 
2015). Furthermore, it has recently been reported that 
statin-induced myopathy is associated with a direct inhi-
bition of mitochondrial complex III at the  QO ubiquinone 
site (Schirris et al. 2015), which is known to be a site of 
mitochondrial ROS generation. Additionally, Kwak et al. 
(2012) observed an increase in mitochondrial ROS pro-
duction in primary human myotubes treated with simv-
astatin due to inhibition of the electron transport chain. 
Likewise, in C2C12 myotubes treated with atorvastatin, 
we demonstrated a concentration-dependent inhibition 
of the mitochondrial electron transport chain parallel to 
an increase in mitochondrial ROS production (Bouitbir 
et al. 2016). In addition, in the same study, we observed 
increased ROS production in both human deltoid biopsies 
as well as in the glycolytic skeletal muscle of rats. Direct 
inhibition of complex III activity, which may be related 
to the lack of intermediates of the cholesterol biosynthe-
sis pathway, with a consecutive increase in mitochondrial 
ROS production appears to be a plausible mechanism for 
the observed myotoxicity of atorvastatin. The results of 
Fig. 7  Atorvastatin induces apoptotic pathways. a Immunoblots of 
caspase 3 and cleaved caspase 3, and cleaved caspase 3 expression 
relative to caspase 3 expression. b, c Nuclei were stained with DAPI 
(blue), and TUNEL nuclei were visualized with magenta fluorescein. 
Merged DAPI and TUNEL nuclei from different groups are shown 
and white arrows indicating apoptotic nuclei. Adjacent pictures cor-
respond to a magnification of the red square area. Merged TUNEL 
images of b superficial gastrocnemius and c vastus intermedius muscle 
sections. d Apoptotic index calculated from TUNEL staining. Results 
are expressed as mean ± SEM; *p < 0.05, **p < 0.01. WT-CTL: 
untreated wild-type mice (n = 13); WT-ATO: wild-type mice treated 
with oral atorvastatin (5  mg/kg/day) 2  weeks (n = 11); KO-CTL: 
untreated PGC-1β(i)skm−/− mice (n = 8); KO-ATO: PGC-1β(i)skm−/− 
treated with oral atorvastatin (5  mg/kg/day) for 2  weeks (n = 11). 
(Color figure online)
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the current and our previous study (Bouitbir et al. 2016) 
show that in oxidative muscle of wild-type mice, where 
the antioxidative capacity is high, the increase in ROS is 
mild, inducing the expression of PGC-1α and PGC-1β and 
stimulating mitochondrial proliferation (Liang and Ward 
2006). However, in oxidative muscle without expression 
of PGC-1β and in glycolytic muscle of wild type and PGC-
1β(i)skm−/− mice, the statin-associated rise in ROS is much 
more accentuated, leading to a down-regulation of mito-
chondrial biogenesis and induction of apoptosis (Fig. 8).
The results of the current study support previous obser-
vations showing that muscle phenotype and the related 
mitochondrial content are key factors in statin-associated 
myotoxicity (Bonifacio et al. 2016). Furthermore, they dem-
onstrate a role for PGC-1β in statin-associated myotoxic-
ity, which is related to the important function of PGC-1β 
in mitochondrial proliferation and maintenance of mito-
chondrial antioxidative capacity. Interestingly, taking into 
account the clinical context, mutations of PGC-1β can rep-
resent a risk factor for myotoxicity observed with statins. 
For instance, mice lacking exon 3–4 of PGC-1β showed an 
Fig. 8  Proposed scheme illustrating the action of statins on mitochon-
drial function in wild type and PGC-1β-deficient mice according to 
muscular phenotype. Statins impair mitochondrial function in the 
glycolytic skeletal muscle from wild-type and PGC-1β(i)skm−/− mice, 
leading to the formation of oxidative stress and triggering of apop-
totic pathways. In addition, they shift the fiber composition towards 
a highly glycolytic fiber type. Oxidative muscle contains higher anti-
oxidant defenses that protect this muscle from the action of statins, 
leading to cell survival. However, loss of PGC-1β in oxidative muscle 
is associated with a shift of the fiber composition towards glycolytic 
fibers, mitochondrial dysfunction and oxidative stress, and eventually 
cell death by apoptosis
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impaired mitochondrial function in skeletal muscles (Vianna 
et al. 2006). Moreover PGC-1β expression decreases with 
age in human muscle (Ling et al. 2004). The impact of statin 
adverse effects on skeletal muscle may therefore be more 
accentuated in the elderly, where even modest decreases in 
muscle function can be associated with hospitalization and 
mortality (Walker and Jacobson 2008). The results of the 
current study suggest that increasing PGC-1β expression 
and/or activity in skeletal muscle may help to prevent myo-
toxicity caused by statins.
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